Paul M. Diderichsen

Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial

Faustino Torrico, Joaquím Gascón, Lourdes Ortiz et al. · The Lancet Infectious Diseases · 2018 · 297 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Florence Namour, Paul M. Diderichsen, Eugène Cox et al. · Clinical Pharmacokinetics · 2015 · 136 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

Neeraj Gupta, Paul M. Diderichsen, Michael J. Hanley et al. · Clinical Pharmacokinetics · 2017 · 43 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16

Modelling the Electrical Activity of Pancreatic α-cells Based on Experimental Data from Intact Mouse Islets

Paul M. Diderichsen, Sven Göpel · Journal of Biological Physics · 2006 · 29 citations · Full text

Life Sciences, Cell Biology, Physiology +17

Operating characteristics of stepwise covariate selection in pharmacometric modeling

Malidi Ahamadi, Anna Largajolli, Paul M. Diderichsen et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2019 · 27 citations

Pharmacy, Pharmacokinetics, Pharmacology +12